<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/252311-novel-compounds-as-bradykinin-receptor-antagonist-and-composition-therefrom by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:26:20 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 252311:NOVEL COMPOUNDS AS BRADYKININ RECEPTOR ANTAGONIST AND COMPOSITION THEREFROM</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">NOVEL COMPOUNDS AS BRADYKININ RECEPTOR ANTAGONIST AND COMPOSITION THEREFROM</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>There is disclosed compounds of general formula (I) in which R is hydrogen or methyl; W is a single bond or an oxygen atom; n = 3; X is hydrogen or a -NR1R2 group in which R1 and R2 are hydrogen; Y is a -NR3R4R5 group in which R3, R4, R5 are methyl; and the pharmaceutically acceptable salts, enantiomers and enantiomeric mixtures thereof.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>The activation of bradykinin B1 and B2 receptors induces relaxation of<br>
vasal muscles with consequent hypotension, increase in vascular permeability,<br>
contraction of smooth muscles of intestine and respiratory tract, stimulation of<br>
nociceptive neurons, alteration of ionic epithelial secretion, production of<br>
nitroxide and release of cytokines by leukocytes and eicosanoids from<br>
different cell types. As a consequence, antagonistic compounds of BK<br>
receptors can be considered a novel class of medicaments supposedly active in<br>
various disorders. Possible therapeutical applications for said antagonists are<br>
inflammatory, allergic and autoimmune disorders, such as asthma and chronic<br>
bronchitis (also induced by irritants), allergic, vasomotor and viral rhinitis,<br>
obstructive pulmonary disease (COPD), rheumatoid arthritis, chronic<br>
inflammatory diseases of the bowel (Crohn's disease and ulcerative colitis),<br>
glomerulonephritis, psoriasis, rash, acute and chronic cystitis; degenerative<br>
disorders characterized by fibrosis, such as hepatic cirrhosis, glomerulopathies<br>
and pulmonary fibrosis, arteriosclerosis; thanks to their analgesic activity, in<br>
the treatment of both acute and chronic pain, for example in burns, cephalea,<br>
insects bites, chronic pain in cancer patients; in disorders of the cardiovascular<br>
apparatus such as septic, allergic and post-traumatic shocks, and hepatic<br>
cirrhosis by hepatorenal syndrome; as anticancer and antiangiogenetics; in the<br>
treatment of hypotension and of alopecia.<br>
Different peptide and non-peptide antagonists of bradykinin B2 receptor<br>
are known in literature. W003103671 discloses a large family of compounds<br>
with antagonistic activity on bradykinin B2 receptor. The compounds of the<br>
present invention, although being included in the general formula of<br>
W003103671, are not described or characterized in said document.<br>
DETAILED DISCLOSURE<br>
The present invention relates to non-peptide compounds which show<br>
high affinity and antagonistic activity towards B2 receptor, having general<br><br>
AMENDED 1<br>
DETAILED DISCLOSURE<br>
The present invention relates to non-peptide compounds which show<br>
high affinity and antagonistic activity towards B2 receptor, having general<br>
formula (I): <br>
in which<br>
-	R is hydrogen or methyl;<br>
-	W is a single bond or an oxygen atom;<br>
n= 3;<br>
-	X is hydrogen or a -NR1R2 amino group in which R1 and R2 can be<br>
independently hydrogen or a group selected from methyl, ethyl, n-<br>
propyl, isopropyl;<br>
-	Y is a -NR3R4R5 quaternary ammonium group in which R3, R4, R5<br>
can be independently a group selected from methyl, ethyl, n-propyl,<br>
isopropyl, n-butyl, isobutyl, n-pentyl; and<br>
the salts thereof with pharmaceutically acceptable acids.<br>
Preferably, compounds (I) are saltified with inorganic or organic acids<br>
selected from hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric,<br>
acetic, trifluoroacetic, propionic, oxalic, malic, maleic, succinic, malonic,<br>
aspartic, glutamic acids. Moreover, due to the presence of a chiral center, the<br>
invention also comprises the two enantiomers or mixtures thereof, in any<br><br>
antagonistic activity towards B2 receptor higher than the more structurally-<br>
similar analogues as described in W003103671.<br>
Preferred are the compounds of general formula (I) in which:<br>
n = 3;<br>
X = hydrogen or a -NH2 group;<br>
Y	= -N(CH3)3+ quaternary ammonium group;<br>
the other substituents being as defined above.<br>
Particularly preferred are the compounds (I) wherein:<br>
R is hydrogen.or methyl;<br>
W is an oxygen atom;<br>
n = 3;<br>
X is hydrogen or a group -NH2;<br>
Y	is a -N(CH3)3+ quaternary ammonium group.<br>
The compounds object of the present invention can be prepared<br>
according to well known synthetic routes.<br>
Preferably, the compounds of general formula (I) as defined above are<br>
prepared by condensation, in the presence of a suitable condensing agent, of<br>
the intermediate of general formula (II), obtained as disclosed in<br>
W003103671 <br>
with the compound of formula (10)<br><br><br>
or a derivative thereof in which the carboxylic group is suitably<br>
activated.<br>
The synthetic process is illustrated in Scheme 1<br><br>
Scheme 1<br>
The compound of formula (2) is prepared as described in J. Med. Chem.<br>
2001, 44, 1674-1689 by bromination of the corresponding toluene derivative,<br>
which is in turn obtained as described in J. Fluorine Chemistry, 2000. 101:85-<br>
89.<br>
The first step concerns' the formation of the sulfonamido bond (4)<br><br>
obtained by condensation of intermediates (2) and (3). This reaction is carried<br>
out at room temperature, preferably in acetonitrile/water (2:1), in the presence<br>
of sodium hydrogen carbonate (NaHC03). Said reaction takes place with<br>
exchange of chlorine and bromine at the benzyl position: the resulting<br>
products mixture is directly used in the subsequent step. The reaction of the<br>
halogen derivatives mixture with a disubstituted hydroxyquinoline (5), in the<br>
presence of potassium carbonate (K2CO3) and potassium iodide (KI), in<br>
acetone under reflux, yields the ester derivative (6).<br>
Compound of formula (5) i.e. 2,4-dimethyl-8-hydroxy quinoline, in<br>
which R4=R5=CH3, is prepared as disclosed in W09640639.<br>
The methyl ester of formula (6) is hydrolysed under basic conditions to<br>
carboxylic acid (7), which is condensed with Boc-piperazine (8), to yield<br>
intermediate (9). Said condensation reaction is carried out according to a<br>
known procedure for the peptide synthesis, using hydroxybenzotriazole to<br>
activate the carboxylic moiety, a condensing agent such as l-ethyl-3-(3'-<br>
dimethylpropyl) carbodiimide and an amount of tertiary amine, namely<br>
diisopropylethylamine, of three equivalents on the basis of the condensing<br>
agent. Compound (II) is obtained by cleavage of the Boc group from<br>
intermediate (9), by means of a hydrochloric acid solution (4N) in dioxane and<br>
isolating the free amine instead of the hydrochloride.<br>
Derivative (11) is obtained by condensation of intermediate (10) with<br>
the amino acid (11) according the procedure described for the preparation of<br>
(9) from (7). Any Boc group present can be removed from intermediate (11),<br>
with a hydrochloric acid solution (4N) in dioxane, thus obtaining the final<br>
compound. When case the trialkylammonium group is not present in any<br>
commercially available intermediates, it can be synthesized starting from the<br>
corresponding amine with known procedures (Rapoport et al, J. Org. Chem,<br>
1977, 42:139-141; Chen et al, J. Biochem., 1978, 5δ:150-152).<br><br>
The compounds of the invention are used in the treatment of all those<br>
disorders in which the activation of bradykinin receptor has to be blocked or<br>
reduced. They are particularly suitable for the treatment of inflammatory,<br>
allergic and autoimmune disorders, such as asthma and chronic bronchitis,<br>
allergic, vasomotor and viral rhinitis, chronic obstructive pulmonary disease<br>
(COPD), rheumatoid arthritis, chronic inflammatory diseases of the bowel<br>
(Crohn's disease and ulcerative colitis), glomerulonephritis, psoriasis, rash,<br>
acute and chronic cystitis, hepatic cirrhosis, glomerulopathies and pulmonary<br>
fibrosis, arteriosclerosis, both acute and chronic pain, septic, allergic and post-<br>
traumatic shocks, hepatic cirrhosis by hepatorenal syndrome, hypotension,<br>
alopecia, or as anticancer and antiangiogenetics.<br>
For use in therapy, the compounds of the invention will be suitably<br>
formulated together with pharmaceutically acceptable carriers/excipients.<br>
Preferred are pharmaceutical forms suitable for the oral administration, such<br>
as tablets, capsules, granules, powders, solutions, suspensions, syrups or the<br>
like. These pharmaceutical preparations can be prepared with conventional<br>
procedures using ingredients known in technique, such as ligands,<br>
disintegrants, lubricants, fillers, stabilizing agents, diluents, dyes, flavours,<br>
wetting agents and other excipients known to those skilled in the art. The oral<br>
formulations also comprise protracted-release forms, such as enteric-coated<br>
tablets or granules. The solid oral compositions can be prepared with<br>
conventional mixing, filling or compression methods. The liquid oral<br>
preparations can be in the form of, for example, aqueous or oily suspensions<br>
or solutions, emulsions, syrups, or can be presented as dry product for<br>
reconstitution with water or other suitable carrier before use.<br>
The dosage can range depending on the age and general conditions of<br>
the patient, nature and severity of the disease or disorder and route and type of<br>
administration. As a rule, in case of oral administration to a human adult<br><br>
patient, the compounds' of the) present invention will be generally administered<br>
in a total daily dosage ranging from 1 to 1000 mg, preferably from 5 to<br>
300 mg, in a single dose or in subdivided doses.<br>
The following examples illustrate the invention in greater detail.<br>
EXAMPLE 1<br>
(4-(S)-amino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-<br>
benzenesulfonylamino]tetrahydropyran-4-carbonyl}piperazin-l-yl)-5-oxo-<br>
pentyl]trimethyl-ammoriium chloride, dihydrochloride<br>
(Compound of general formula I in which R = CH3, W = -0-, X = NH2,<br>
n = 3, Y = N(CH3)3+Cl).<br>
The compound is synthesized following the synthetic route illustrated in<br><br><br>
GENERAL METHODS: analytic HPLC: Flow: 1 ml/min; Mobile<br>
phase: A-0.1% trifluoroacetic acid in water, B-0.1% trifiuoroacetic acid in<br>
acetonitrile; Column: Zorbax Eclipse XDB C8, 5 micron, 150 x 4,6 mm.<br>
Intermediate (2) 2,4-Dichloro-3-bromomethyl-benzenesulfonyl chloride<br>
10 ml of chlorosulfonic acid are dropwise added with 4.8 ml of 2,6-<br>
dichtorotoluene in two hours, under magnetic stirring at room temperature.<br>
After completion of the addition, the mixture is heated at 40°C for two hours,<br>
thereby obtaining a purple solution, which is cooled and carefully poured into<br>
ice-water (0.5 1), stirring vigorously. The separated white solid is filtered,<br>
triturated, washed with water, dried over KOH and purified by washing with<br>
n-hexane, adding 200 ml of solvent under strong stirring. The mixture, is<br>
filtered, the solid is discarded and the solvent is evaporated to dryness to<br>
obtain 2,4-dichloro-3-methyl-benzenesulfonyl chloride as a crystalline white<br>
solid. Yield: 85%.<br>
HPLC purity: 86% (30% B, 3%/min, Rt=19.7 min).<br>
1H-NMR (CDC13): δ (ppm) 2.6 (s, 3H), 7.5 (d, 1H), 7.95 (d, 1H);<br>
ESI(+)MS: m/z 260 [M+H]+.<br>
This intermediate is brominated under the following conditions:<br>
20 mmols of 2,4-dichloro-3-methyl-benzenesulfonyl chloride are dissolved in<br>
acetonitrile. 2 eq of NBS are added under stirring at room temperature until<br>
completed solubilization of NBS. Finally, 0.1 eq of azo-bisisobutyronitrile<br>
(AIBN) is added and the mixture is heated at 70°C for approx. 6 hours. The<br>
solution is evaporated, the residue is taken up with ethyl acetate, washed with<br>
H20 and 5% NaHC03, dried over dry Na2S04 and filtered. The organic phase<br>
is evaporated thereby obtaining a viscous, light colored liquid which is taken<br>
up into petroleum ether. The residue is filtered, and the solution yields (2') as<br>
a light colored crystalline solid.'<br>
HPLC purity: 95% (50% B to 5%/min, Rt=18.72).<br><br>
!H-NMR (CDCl3): δ (ppm) 4.85 (s, 2H), 7.58 (d, 1H), 8.08 (d, 1H);<br>
ESI(+)MS: m/z 338.1 [M+H+.<br>
Intermediate (3') 4-Amino-tetrahydropyran-4-carboxylic acid methyl ester<br>
hydrochloride<br>
4-Amino-tetrahydropyran-4-carboxylic acid hydrochloride (0.025 mols)<br>
is suspended in 13 ml of CH3OH, cooled to -60°C and dropwise added with<br>
SOCl2 (3 eq) under stirring. After completion of the addition, the mixture is<br>
left to warm to room temperature, then gradually heated to ebullition to obtain<br>
a clear solution (approx. 2 hours), which is cooled, the residue is filtered and<br>
concentrated under vacuum.<br>
Yield 80%. Purity (NMR): 85%.<br>
1H-NMR (DMSO-d6): δ (ppm) 1.91-2.04 (m, 4H), 3.78 (s, 3H), 3.60-<br>
3.85 (m, 4H), 9.00 (s, 3H). ESI(+)MS: m/z 160.1 [M+H]+.<br>
Intermediate (4') 4-(3-Bromomethyl-2,4-dichloro-benzenesulfonylammo)-<br>
tetrahydropyran-4-carboxylic acid methyl ester<br>
The intermediate (3') (1.1 eq) is dissolved in water together with 4<br>
equivalents of K2CO3. This solution is added with a solution of 1 equivalent<br>
(10 mmols) of intermediate (2) in acetonitrile and stirred at room temperature<br>
until a precipitate forms (4 hours). The solvent is evaporated off and the<br>
residue is dissolved in ethyl acetate and 0.1M HC1 (1/1). The organic phase is<br>
separated and dried over Na2S04. The solvent is evaporated off, the resulting<br>
solid is washed with cyclohexane, thereby obtaining a white solid in which<br>
chloro/bromo derivatives are present in 10/1 ratio. Yield: 60%.<br>
HPLC purity: 88% (20% B at 3%/min; Rt=14.11 (Br) and 14.47 (Cl)).<br>
1H-NMR (CDCl3): δ (ppm) 1.81-1.99 (2H, m), 2.07-2.25 (2H, m), 3.49-<br>
3.71 (7H, m), 4.81 (1.5H, s, [Br]), 4.94 (0.3H, s, [Cl]), 5.30 (1H, brs),<br>
7.47-7.53 (1H, m), [7.49 (d, J 8.5Hz, X = Br), 7.51 (d, J 8.5Hz, X = Cl],<br>
7.91-7.98 (1H, m), [7.94 (d, J 8.5Hz, X - Br), 7.96 (d, J 8.5Hz, X = Cl].<br><br>
Intermediate (6') 4-[2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl')-<br>
benzenesulfonylamino]tetrahydropyran-4-carboxylic acid methyl ester<br>
Quinoline (5') (0.48 mmols) and LiOH (2.5 eq) are mixed at room<br>
temperature under nitrogen in methyl ethyl ketone (MEK). The mixture is kept<br>
under stirring and under nitrogen for 90 min. Intermediate (4) is dissolved in<br>
MEK/dry DMF (2/1) (42 ml, 12 ml/mmol), and the solution containing the<br>
quinoline is dropwise added to the reaction mixture, under stirring. Stirring is<br>
kept for 16 hours. The reaction mixture is concentrated under vacuum and the<br>
residue dissolved in ethyl acetate (50 ml, 100 ml/mmol). The organic phase is<br>
washed (3x50 ml) with a buffer solution pH=4.2, dried over Na2SO4, filtered<br>
and concentrated under vacuum to obtain a yellow oil. Yield: 33%. HPLC<br>
purity: 77% (20% B, 3%/min; Rt=9.54).<br>
1H-NMR (DMSO-d6): δ (ppm) 1.80-1.95 (m, 4H), 2.56 (s, 3H), 2.64 (s,<br>
3H), 3.32-3.40 (m, 2H), 3.42-3.55 (m, 2H), 3.60 (s, 3H), 5.57 (s, 2H),<br>
7.30 (s, 1H), 7.39 (d, 1H), 7.50 (dd, 1H), 7.67 (d, 1H), 7.78 (d, 1H),<br>
8.02 (d, 1H), 8.77 (bs, 1H); ESI(+)MS: m/z 553.1 [M+H]+.<br>
Intermediate (7') 4-[2,4-Dichloro-3-(2,4-dimethyI-qumolin-8-yloxymethyl)-<br>
benzenesulfonylamino]tetrahydropyran-4-carboxvlic acid<br>
Intermediate of formula (6') is dissolved in THF and the solution is<br>
added with 10 eq of 1M LiOH in water. The mixture is stirred for 4 hours at<br>
40°C, then the solvent is evaporated off. The residue is dissolved in water and<br>
0.1M HC1 is added to pH=4. The aqueous phase is extracted with<br>
dichloromethane and the organic phase is dried over Na2S04. Solvent is<br>
evaporated off and to obtain a yellow solid residue. Yield: 90%. HPLC purity:<br>
99% (20%B, 3%/min; Rt=7.72).<br>
1H-NMR (DMSO-d6): δ (ppm) 1.75-1.90 (m, 4H), 2.56 (s, 3H), 2.64 (s,<br>
3H), 3.10-3.35 (m, 2H), 3.38-3.50 (m, 2H), 5.58 (s, 2H), 7.30 (s, 1H),<br><br>
7.37 (d, 1H), 7.46 (t, 1H), 7.67 (d, 1H), 7.75 (d, 1H), 8.03 (d, 1H), 8.64<br>
(bs, 1H). ESI(+)MS: m/z 539.1 [M+H]+.<br>
Intermediate (9') 4-tert-butoxycarbonyl-((4-(2.4-dichloro-3-(2,4-dimethyl-<br>
quinolin-8-yloxymethyl)benzenesulfonylamino)-tetrahydropyran-4-carbonyl)-<br>
piperazin-l-yl)<br>
(7') (1.3 mmols) and HOBt (1.1 eq) are suspended in 50 ml of dry DMF<br>
in a 100 ml round-bottom flask under nitrogen. The mixture is cooled to +4°C<br>
and added with EDCI HCI(1.1 eq) under stirring. Stirring at +4°C is<br>
continued for an hour, then DIPEA (2 eq) and Boc-piperazine (1 eq) are added<br>
and the mixture is left to warm to room temperature, under stirring. After 12 h<br>
the solvent is evaporated off, the residue is dissolved in 40 ml of DCM and the<br>
organic phase is washed with brine (20 ml) and dried over Na2S04. The<br>
solvent is evaporated off to obtain an oil which is purified on a Varian Mega<br>
Bond (flash master system) 70 g column (ethyl acetate, Rf=0.50), thereby<br>
obtaining a yellow solid.<br>
Yield: 96%. HPLC purity: 98% (20% B, 3% B/min, Rt=11.14).<br>
1H-NMR (CDC13): δ (ppm) 1.45 (s, 9H); 1.55-1.80 (m, 2H), 2.05-2.20<br>
(m, 4H), 2.56 (s, 3H), 2.64 (s, 3H), 3.38-3.90 (m, 10H), 5.58 (s, 2H),<br>
7.10 (s, 1H), 7.30 (s, 1H), 7.37 (d, 1H), 7.46 (t, 1H), 7.67 (d, 1H), 7.75<br>
(d, 1H), 8.03 (d, 1H), 8.64 (bs, 1H). ESI(+)MS: m/z 707.2 [M+H]+.<br>
Intermediate (1) (4-(2,4-Dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-<br>
benzenesulfonylamino)-tetrahydropyran-4-carbonyl)-piperazin-l-yl<br>
0.62 mmols of (9') are added with 10 ml of HCl/dioxane 4M and the<br>
mixture is kept under stirring for 3 hours. The solvent is evaporated off and<br>
the residue is freeze-dried, to obtain hydrochloride (1') as yellow solid. Yield:<br>
98%. HPLC purity: 92% (20% B, 3%/min; Rt-5.34).<br>
1H-NMR (D20): δ (ppm) 1.55-2.10 (m, 7H), 2.90-3.10 (m, 9H), 3.20-<br>
3.55 (m, 9H), 6.0 (s, 2H), 7.60-8.10 (m, 8H), 8.95 (d, 1H).<br><br>
ESI(+)MS: m/z 609.1 [M+H]+.<br>
Intermediate	(10')	(4-tert-butoxycarbonylammo-4-carboxy-butyl)-<br>
trimethylammonium<br>
10 mmols of Boc-Orn-OH are suspended in methanol (20 ml) and the<br>
suspension is added with 44 mmols of isourea. The flask is plugged and kept<br>
under stirring at room temperature for 2 days. The resulting solution is<br>
monitored by TLC (eluent: CHCl3/CH3OH/NH4OH 40/54/6; Boc-Orn-OH<br>
Rf=0.29; (10') Rf: 0.11, detection KMn04).<br>
Methanol is evaporated off under vacuum and the residue is digested in<br>
150 ml of water and filtered. The round-bottom flask and the solid are washed<br>
with water (2x50 ml) and all the washing aqueous fractions are combined,<br>
then concentrated under vacuum (40 ml). The resulting solid (4.068 g) is<br>
suspended in water (40 ml), filtered (to remove any traces of urea) and<br>
purified by FCC on reversed phase LiChroprep RP-18 (40-63 micron). The<br>
column (19 x 7 cm) is eluted with 3% CH3CN in water and the fractions<br>
(approx. 100 ml) are analyzed by TLC. The fractions containing the pure<br>
product (500 ml) are combined, concentrated under vacuum to remove<br>
CH3CN, freeze-dried, and finally evaporated from 150 ml of absolute ethanol,<br>
to give 442 mg of a white, highly hygroscopic solid. Yield: 16%.<br>
1H-NMR (DMSO-d6): δ (ppm) 1.38 (s, 9H) 1.58-1.75 (m, 4H), 3.03 (s,<br>
9H), 3.29 (m, 2H), 3.45 (m, 1H), 6.49 (d, d, 1H); ESI(+)MS: m/z 275.2<br>
[M+H]+.<br>
Intermediate (11') r4-(S)-tert-Butoxycarbonylamino-5-(4-(4-[2,4-dichloro-3-<br>
(2,4-dimethyl-quinolin-8-yloxymethyl)benzenesulfonylamino]tetrahydro-<br>
pyran-4-carbonyl}piperazin-l-yl)-5-oxo-pentyl|trimethyl-ammonium chloride<br>
Intermediate (10'), 1.2 mmols, is dissolved in DMF and the solution is<br>
added with dicyclohexylcarbodiimide (1.2 eq) and HOBt (1.2 eq). The mixture<br>
is kept under stirring for 30 min, then added with diisopropylaminomethyl-<br><br>
polystyrene (1.5 eq) and intermediate (V) (1 eq). The mixture is left under<br>
stirring for 24 hours. The resin is filtered, the solvent is evaporated off and the<br>
residue is dissolved in water and ethyl acetate. The aqueous phase is separated<br>
and freeze-dried. The crude product is purified by preparative HPLC (column<br>
Vydac 218TP, C18, 250x50 mm, flow 60 ml/min, gradient 10% to 70%<br>
CH3CN/0.1% TFA in 120 min, detector UV at 240 nm, collection 55 to 75<br>
min) thereby affording intermediate (11') which is freeze-dried as a white<br>
solid. Yield: 46%, HPLC purity: 98% (20% B, 3%/min; Rt=7.68).<br>
'HNMR (DMSO-dg) δ: 1.4 (s, 9H), 1.8-1.45 (m, 6H), 1.95-1.85 (m,<br>
2H), 2.81 (m, 6H), 3.08 (s, 9H), 3.70-3.18 (m, 7H), 4.01-3.56 (5H, m),<br>
4.57-4,45 (m, 1H), 5.59 (s, 2H), 7.25 (d, 1H), 7.90-7.43 (m, 4H), 8.02<br>
(d, 1H), 8.85 (s, 1H). ESI(+)MS: m/z 863.2 [M+H]+.<br>
(4-(S)-Amino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-<br>
benzenesulfonylamino]tetrahydropyran-4-carbonyl}piperazin-1 -y1)-5 -oxo-<br>
pentyl]trimethyl-ammonium chloride, dihydrochloride •<br>
0.45 mmols. of (11') are added with 10 ml of HCl/dioxane 4M. The<br>
mixture is kept under stirring for 6 hours, the solvent is evaporated off and the<br>
residue is freeze-dried, thereby obtaining the final compound as a white solid.<br>
Yield: 87%. HPLC purity: 98% (20% B, 3%/min; Rt=5.14).<br>
JH NMR (DMSO-d6) δ: 1.95-1.60 (m, 8H), 2.81 (m, 6H), 3.08 (s, 9H),<br>
3.70-3.18 (m, 12H), 4.57-4,45 (m, 1H), 5.59 (s, 2H), 7.90-7.60 (m, 4H), 8.02<br>
(d, 1H), 8,5 (s, 3H), 8.85 (s, 1H).<br>
ESI(+)MS: m/z 763.1 [M+H]+.<br>
EXAMPLE 2<br>
(4-(S)-Amino-5-(4-(4-(2,4-dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-<br>
benzenesulfonylamino)tetrahydropyran-4-carbonyl)-piperazin-l-yl-)5-oxo-<br>
pentyl)-trimethylammonium chloride, hydrochloride<br><br>
1H NMR (DMSO-d6) δ: 8.90 (1H, s), 8.47-8.34 (4H, m), 8.02 (1H, d),<br>
7.81 (1H, d), 7.73-7.37 (4H, m), 5.62 (2H, s), 4.57-4,45 (1H, m), 4.01-3.56<br>
(5H, m), 3.43-3.18 (7H, m), 3.06 (9H, s), 2.78-2.61 (4H, m), 2.89 (1H, s),<br>
1.97-1.60 (9H, m). HPLC: tR = 9.26 min. MS: [M]+749.<br>
EXAMPLE 3<br>
[5-(4-{4-[2,4-Dichloro-3-(2,4-dimethyl-qxinolin-8-yloxymethyl)-benzene-<br>
sulfonylamino]tetrahydropyran-4-carbonyl}piperazin-l-yl)-5-oxo-pentyl]-<br>
trimethyl-ammoniumtrifluoroacetate.<br>
1H-NMR (DMSO-d6): δ (ppm) 1.53 (s, 2H, m); 1.69 (m, 4H); 1.90 (m, 2<br>
H); 2.45 (t, 2 H); 2.78 (m, 6 H); 3.04 (9 H, s); 3.23 - 3.57 (7 H, m); 5.68 (2H,<br>
s); 7.38-8.18 (5 H, m); 8.04 (1H, d, J = 8.42 Hz); 8.82 (1 H, s). HPLC:<br>
tR = 5.65min. MS: [M]+748.<br>
EXAMPLE 4<br>
[4-(S)-Amino-5-(4-{l-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-<br>
benzenesulfonylamino]cyclopentanecarbonyl}piperazin-l-yl)-5-oxo-pentyl]-<br>
trimethyl-ammonium chloride, dihydrochloride.<br>
!H NMR (DMSO-d6) δ: 8.90 (1H, s), 8.48 (3H, s), 8.02 (1H, d), 7.95-<br>
7.63 (3H, m), 5.59 (2H, s), 4.57-4,45 (1H, m), 3.97-3.24 (10H, m), 3.08 (9H,<br>
s), 2.95-2.61 (5H, m), 1.97-1.72 (8H, m), 1.42 (4H, s); HPLC: tR = 5.88 min.<br>
MS: [M]+747.2.<br>
Biological Activity<br>
The evaluation of the B2 receptor affinity of the compounds of the<br>
present invention was carried out with studies of binding to the human B2<br>
receptor expressed in CHO cells, following the procedure described by<br>
Bellucci et al, Br. J. Pharmacol. 2003, 140:500-506; the binding values are<br>
reported expressed as pKi.<br>
Antagonistic activity (expressed as pA2) was evaluated as the inhibition<br>
of the bradykinin-induced production of inositols in CHO cells transfected<br><br>
with B2 human receptor, according to the procedure described in Bellucci et<br>
al, Br. J. Pharmacol. 2003, 140:500-506.<br>
The in vivo activity of the compounds of the present invention was<br>
evaluated as effectiveness in inhibiting BK-induced bronchospasm in the<br>
guinea pig (Tramontana et al., J. Pharmacol. Exp. Therap., 29δ:1051-1057,<br>
2001), measuring the it dose (it=intratracheal administration) (in nmols/kg)<br>
which inhibited by 80% bronchial constriction for at least 210 min.<br><br><br>
The preferred compounds of the present invention were compared with<br>
those more structurally similar disclosed in W003103671. It has surprisingly<br>
been found that the compounds of the invention have in vivo and in vitro<br>
activities higher than the structurally related analogues of W003103671. Both<br>
the antagonistic activity test on cells transfected with the human receptor and<br>
the in vivo test are highly predictive of the expected dose for therapeutical<br>
applications in humans.<br>
ABBREVIATIONS<br>
it = intratracheal administration; iv - intravenous administration; eq = equivalent;<br>
DCM = dichloromethane; MeOH = methanol; THF = tetrahydrofuran; DMSO =<br>
dimethylsulfoxide; DMF = dimethylformamide; AcOEt = ethyl acetate; AcOH =<br>
acetic acid; TFA = trifluoroacetic acid; NBS = Nɑ-bromosuccinimide; bpo =<br>
benzoyl peroxide; Boc = tert-butoxycarbonyl; HOBt = 1-hydroxy-benzotriazole;<br>
EDC =	l-ethyl-3-(3'-dimethylpropyl)carbodiimmide; DIPEA<br>
diisopropylethylamine; HPLC = high pressure liquid chromatography; TLC =<br>
thin-layer chromatography; NMR = nuclear magnetic resonance;<br>
ESI = electron spray ionization; MS = mass spectrometry; FCC = Flash Column<br>
Chromatography; Rt = retention time.<br><br><br>
WE CLAIM:<br>
1. Compounds of general formula (I)<br><br>
in which<br>
R is hydrogen or methyl;<br>
W is a single bond or an oxygen atom;<br>
n = 3;<br>
X is hydrogen or a -NR1R2 group in which R1 and R2 are hydrogen;<br>
Y is a -NR3R4R5 group in which R3, R4, R5 are methyl; and<br>
the pharmaceutically acceptable salts, enantiomers and enantiomeric mixtures thereof.<br>
2.	Compounds as claimed in claim 1 wherein the pharmaceutically acceptable salts are<br>
selected from hydrochloric and trifluoroacetic acids.<br>
3.	Compounds as claimed in claim 1, wherein:<br>
W is a single bond;<br>
n = 3;<br>
X is selected from hydrogen or a -NH2 group;<br>
Y is a -N(CH3)3+ quaternary ammonium group;<br>
R is hydrogen or methyl.<br><br>
4.	Compounds as claimed in claim 1 or 2, in which:<br>
R is selected from hydrogen or methyl;<br>
W is an oxygen atom;<br>
n=3;<br>
X is selected from hydrogen or a -NH2 group;<br>
Y is a -N(CH3)3+ quaternary ammonium group.<br>
5.	The compound as claimed in claim 3, which is:<br>
[4-(S)-amino-5-(4-{1-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-<br>
yloxymethyl)benzenesulfonylamino]-cyclopentanecarbonyl}piperazin-1-yl)-5-oxo-<br>
pentyl]trimethyl-ammonium chloride, dihydrochloride<br>
6.	The compounds as claimed in claim 4, which are:<br><br>
•	(4-(S)-amino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxy-<br>
methyl)benzenesulfonylamino]tetrahydropyran-4-carbonyl}-piperazin-1-yl)-5-oxo-<br>
pentyl]trimethyl-ammonium chloride, dihydrochloride;<br>
•	(4-(S)-amino-5-(4-(4-(2,4-dichloro-3-(2-methyl-quinolin-8-yloxy-methyl)-<br>
benzenesulfonylamino)-tetrahydropyran-4-carbonyl)-piperazin-1-yl-)5-oxo-pentyl)-<br>
trimethyl-ammonium chloride, hydrochloride;<br>
•	[5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-<br>
benzenesulfonylamino]tetrahydropyran-4-carbonyl}piperazin-1-yl)-5-oxo-<br>
pentyl]trimethyl-ammonium trifluoroacetate.<br><br>
7.	Pharmaceutical compositions comprising a compound, as claimed in claim 1, as the<br>
active ingredient together with pharmaceutically acceptable excipients, such as herein<br>
described.<br>
8.	Composition as claimed in claim 7, which is capable of being used for the treatment<br>
of all the conditions in which activation of bradykinin B2 receptors is involved.<br><br>
9.	Composition as claimed in claim 7, which is capable of being used for the treatment<br>
of inflammatory, allergic and autoimmune conditions.<br>
10.	Composition as claimed in claim 7, which is capable of being used for the treatment of<br>
asthma and chronic bronchitis, allergic, vasomotor and viral rhinitis, chronic obstructive<br>
pulmonary disease (COPD), rheumatoid arthritis, chronic inflammatory diseases of the bowel<br>
(Crohn's disease and ulcerative colitis), glomerulonephritis, psoriasis, rash, acute and chronic<br>
cystitis, hepatic cirrhosis, glomerulopathies and pulmonary fibrosis, arteriosclerosis, both acute<br>
and chronic pain, septic, allergic and post-traumatic shocks, hepatorenal syndrome by hepatic<br>
cirrhosis, hypotension, alopecia, cancer and antiangiogenetic diseases.<br><br><br>
There is disclosed compounds of general formula (I)<br><br>
in which<br>
R is hydrogen or methyl;<br>
W is a single bond or an oxygen atom;<br>
n = 3;<br>
X is hydrogen or a -NR1R2 group in which R1 and R2 are hydrogen;<br>
Y is a -NR3R4R5 group in which R3, R4, R5 are methyl; and<br>
the pharmaceutically acceptable salts, enantiomers and enantiomeric mixtures thereof.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1hc3NpZ25tZW50LnBkZg==" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-assignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1jbGFpbXMxLjAucGRm" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-claims1.0.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1jbGFpbXMxLjEucGRm" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-claims1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-correspondence others 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1mb3JtIDMgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-form 3 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIGV4bSByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-international exm report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1wY3Qgb3RoZXJzLnBkZg==" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-pct others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1wY3QgcmVxdWVzdC5wZGY=" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-pct request.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDEyOTUta29sbnAtMjAwNy1wcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">01295-kolnp-2007-priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LSgxNy0wMi0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-(17-02-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LSgyNy0xMC0yMDExKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-(27-10-2011)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LSgyNy0xMC0yMDExKS1BTUFOREVEIENMQUlNUy5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-(27-10-2011)-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LSgyNy0xMC0yMDExKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-(27-10-2011)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LSgyNy0xMC0yMDExKS1ERVNDUklQVElPTiAoQ09NUExFVEUpLnBkZg==" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-(27-10-2011)-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LSgyNy0xMC0yMDExKS1GT1JNIDEucGRm" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-(27-10-2011)-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LSgyNy0xMC0yMDExKS1GT1JNIDEzLnBkZg==" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-(27-10-2011)-FORM 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LSgyNy0xMC0yMDExKS1GT1JNIDIucGRm" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-(27-10-2011)-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LSgyNy0xMC0yMDExKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-(27-10-2011)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LSgyNy0xMC0yMDExKS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-(27-10-2011)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFIDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-CORRESPONDENCE 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUZPUk0gMTMgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-FORM 13 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUZPUk0gMTgucGRm" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-FORM 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUZPUk0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUZPUk0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUdQQS5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-GPA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LUdSQU5URUQtU1BFQ0lGSUNBVElPTi5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-GRANTED-SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTI5NS1LT0xOUC0yMDA3LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">1295-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="252310-non-covalent-immobilization-of-indicator-molecules.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="252312-loop-fabric.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>252311</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1295/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>19/2012</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>11-May-2012</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>08-May-2012</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>12-Apr-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>ISTITUTO LUSO FARMACO D&#x27;ITALIA S.P.A.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>VIA WALTER TOBAGI, 8, I-20068 PESCHIERA BORROMEO</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>ROSSI, CRISTINA</td>
											<td>VIA E. BERLINGUER 14., I-00040 POMEZIA</td>
										</tr>
										<tr>
											<td>2</td>
											<td>FELICETTI, PATRIZIA</td>
											<td>VIALE DEI CONSOLI, 27, I-00175 ROMA</td>
										</tr>
										<tr>
											<td>3</td>
											<td>GIOLITTI, ALESSANDRO</td>
											<td>VIA VITTORIO EMANUELE II, 239, I-50134 FIRENZE</td>
										</tr>
										<tr>
											<td>4</td>
											<td>MAGGI, CARLO, ALBERTO</td>
											<td>VIA MICHELAZZI, 43, I-50141 FRIENZE</td>
										</tr>
										<tr>
											<td>5</td>
											<td>QUARTARA, LAURA</td>
											<td>VIA DELLE CASCINE, 22, I-50144 FIRENZE</td>
										</tr>
										<tr>
											<td>6</td>
											<td>FINCHAM, CHRISTOPHER, INGO</td>
											<td>VIALE MANZONI, 51-INT. 4, I-00040 POMEZIA</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 31/47</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2005/010412</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-09-27</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>MI 2004 A 001963</td>
									<td>2004-10-15</td>
								    <td>Italy</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/252311-novel-compounds-as-bradykinin-receptor-antagonist-and-composition-therefrom by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:26:21 GMT -->
</html>
